WO2009148583A3 - Method for improvement of octreotide bioavailability - Google Patents

Method for improvement of octreotide bioavailability Download PDF

Info

Publication number
WO2009148583A3
WO2009148583A3 PCT/US2009/003366 US2009003366W WO2009148583A3 WO 2009148583 A3 WO2009148583 A3 WO 2009148583A3 US 2009003366 W US2009003366 W US 2009003366W WO 2009148583 A3 WO2009148583 A3 WO 2009148583A3
Authority
WO
WIPO (PCT)
Prior art keywords
octreotide
delivery system
release delivery
improvement
flowable composition
Prior art date
Application number
PCT/US2009/003366
Other languages
French (fr)
Other versions
WO2009148583A2 (en
Inventor
Richard L. Norton
Original Assignee
Qlt Usa, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qlt Usa, Inc. filed Critical Qlt Usa, Inc.
Publication of WO2009148583A2 publication Critical patent/WO2009148583A2/en
Publication of WO2009148583A3 publication Critical patent/WO2009148583A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides a an octreotide sustained release delivery system for treatment of diseases ameliorated by octreotide compounds. The sustained release delivery system of the invention includes a flowable composition containing octreotide. Injection of the delivery system results in a biocompatible implant containing the octreotide. The flowable composition includes a poly(lactide-glycolide) copolymer compositions adapted for use in controlled release delivery systems, and exhibits favorable release kinetics for octreotide when implanted in patients.
PCT/US2009/003366 2008-06-03 2009-06-03 Method for improvement of octreotide bioavailability WO2009148583A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5849108P 2008-06-03 2008-06-03
US61/058,491 2008-06-03

Publications (2)

Publication Number Publication Date
WO2009148583A2 WO2009148583A2 (en) 2009-12-10
WO2009148583A3 true WO2009148583A3 (en) 2010-02-04

Family

ID=41037794

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/003366 WO2009148583A2 (en) 2008-06-03 2009-06-03 Method for improvement of octreotide bioavailability

Country Status (1)

Country Link
WO (1) WO2009148583A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102014005782A1 (en) * 2014-04-23 2015-10-29 Martin-Luther-Universität Halle-Wittenberg Injectable and implantable carrier systems based on modified poly (dicarboxylic acid multiol esters) for controlled release of active ingredient
WO2024168022A2 (en) * 2023-02-10 2024-08-15 Tolmar, Inc. Degarelix polymeric formulations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US20060034923A1 (en) * 2004-08-12 2006-02-16 Quest Pharmaceutical Services Pharmaceutical compositions for controlled release delivery of biologically active compounds
WO2006053175A2 (en) * 2004-11-10 2006-05-18 Qlt Usa Inc. A stabilized polymeric delivery system
US20060204540A1 (en) * 2005-03-11 2006-09-14 Petr Kuzma Controlled release formulations of octreotide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US20060034923A1 (en) * 2004-08-12 2006-02-16 Quest Pharmaceutical Services Pharmaceutical compositions for controlled release delivery of biologically active compounds
WO2006053175A2 (en) * 2004-11-10 2006-05-18 Qlt Usa Inc. A stabilized polymeric delivery system
US20060204540A1 (en) * 2005-03-11 2006-09-14 Petr Kuzma Controlled release formulations of octreotide

Also Published As

Publication number Publication date
WO2009148583A2 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
WO2007038246A3 (en) Solid polymer delivery compositions and methods for use thereof
WO2010039641A3 (en) Long term drug delivery devices with polyurethane-based polymers and their manufacture
MX337286B (en) Sustained delivery formulations of risperidone compounds.
EP2309990A4 (en) Drug loaded polymeric nanoparticles and methods of making and using same
WO2007103666A3 (en) Implantable medical endoprosthesis delivery systems
WO2008100576A3 (en) Sustained delivery formulations of rapamycin compounds
WO2010025378A3 (en) Drug delivery implants
WO2006065951A3 (en) Sustained delivery formulations of octreotide compounds
MX341351B (en) Silk polymer-based adenosine release: therapeutic potential for epilepsy.
WO2006017852A3 (en) Pharmaceutical compositions for controlled release delivery of biologically active compounds
WO2009073508A3 (en) Polysaccharide gel compositions and methods for sustained delivery of drugs
DE602005018178D1 (en) PHOSPHOLIPIDE AND POLLUTION-RESISTANT COATING COMPOSITIONS
WO2009005909A3 (en) Biodegradable triblock copolymers for implantable devices
WO2006023130A3 (en) Biodegradable controlled release bioactive agent delivery device
WO2011154724A3 (en) Injectable flowable composition comprising buprenorphine
WO2007092755A3 (en) Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
AU2005304435A8 (en) A stabilized polymeric delivery system
WO2007140312A3 (en) Anti-cross-linking agents and methods for inhibiting cross-linking of injectable hydrogel formulations
WO2007090079A3 (en) Therapeutic agent eluding implant with percutaneous supply
WO2006047378A3 (en) Biocompatible and hemocompatible amphiphilic coatings for drug deliver
WO2007011955A3 (en) Drug-containing implants and methods of use thereof
WO2010105995A3 (en) Zoo-technical drug delivery device
WO2008042748A3 (en) Polyelectrolyte media for bioactive agent delivery
UA105496C2 (en) Delivery of dry formulations of octreotide
WO2011112996A3 (en) Injectable drug delivery system

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09758747

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09758747

Country of ref document: EP

Kind code of ref document: A2